ChiCTR2400090816 版本V1.0 版本创建时间2024/10/14 09:51:32 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2400090816 

最近更新日期:

Date of Last Refreshed on:

2024-10-14 09:51:14 

注册时间:

Date of Registration:

2024-10-14 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

即拔即种结合自体牙骨粉跳跃间隙植骨的临床效果研究:一项回顾性研究

Public title:

Clinical outcome study of immediate extraction and implantation combined with autogenous bone powder jump gap bone grafting: a retrospective study

注册题目简写:

English Acronym:

研究课题的正式科学名称:

即拔即种结合自体牙骨粉跳跃间隙植骨的临床效果研究:一项回顾性研究

Scientific title:

Clinical outcome study of immediate extraction and implantation combined with autogenous bone powder jump gap bone grafting: a retrospective study

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

夏洁 

研究负责人:

丁榆德 

Applicant:

Jie Xia 

Study leader:

Yude Ding 

申请注册联系人电话:

Applicant telephone:

+86 178 5711 4774

研究负责人电话:

Study leader's telephone:

+86 178 2683 1028

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

1137037495@qq.com

研究负责人电子邮件:

Study leader's E-mail:

Dingyude65@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

杭州市拱墅区上塘路158号浙江省人民医院

研究负责人通讯地址:

杭州市拱墅区上塘路158号浙江省人民医院

Applicant address:

Zhejiang Provincial People's Hospital, 158 Shangtang Road, Gongshu District, Hangzhou, China

Study leader's address:

Zhejiang Provincial People's Hospital, 158 Shangtang Road, Gongshu District, Hangzhou, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

310014

申请人所在单位:

浙江省人民医院

Applicant's institution:

Zhejiang Provincial People's Hospital

研究负责人所在单位:

浙江省人民医院

Affiliation of the Leader:

Zhejiang Provincial People’s Hospital

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

浙人医伦审2024其他第(234)号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

浙江省人民医院医学伦理委员会

Name of the ethic committee:

Ethics Committee of Zhejiang Provincial People's Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2024-09-23 00:00:00

伦理委员会联系人:

高寒

Contact Name of the ethic committee:

Han Gao

伦理委员会联系地址:

浙江省杭州市拱墅区上塘路158号

Contact Address of the ethic committee:

158 Shangtang Road, Gongshu District, Hangzhou, Zhejiang, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 571 8589 3643

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

浙江省人民医院

Primary sponsor:

Zhejiang Provincial People's Hospital

研究实施负责(组长)单位地址:

杭州市拱墅区上塘路158号浙江省人民医院

Primary sponsor's address:

Zhejiang Provincial People's Hospital, 158 Shangtang Road, Gongshu District, Hangzhou, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

浙江

市(区县):

杭州市

Country:

China

Province:

Zhejiang

City:

Hangzhou

单位(医院):

浙江省人民医院

具体地址:

浙江省杭州市拱墅区上塘路158号

Institution
hospital:

Zhejiang Provincial People's Hospital

Address:

158 Shangtang Road, Gongshu District, Hangzhou, Zhejiang, China

经费或物资来源:

浙江省人民医院

Source(s) of funding:

Zhejiang Provincial People's Hospital

Target disease:

alveolar bone defect

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

回顾性研究 

Study phase:

Retrospective study

研究设计:

横断面 

Study design:

Cross-sectional 

研究目的:

通过对比分析自体牙骨粉与异种骨在拔牙即种植手术中用于跳跃间隙植骨的效果,探讨自体牙骨粉在骨增量中的临床应用价值。  

Objectives of Study:

The clinical value of autogenous dental bone powder in bone augmentation was explored by comparing and analysing the effect of autogenous dental bone powder and allograft bone used for jump gap bone grafting in tooth extraction i.e. implant surgery.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.已完成跳跃间隙植骨的患者; 2.年龄>18岁; 3.临床及影像学资料完整。

Inclusion criteria

1. patients who have completed a jump gap bone graft; 2. age > 18 years; 3. complete clinical and imaging data.

排除标准:

1.临床及影像学资料不完整; 2.术后失访患者; 3.手术前后6个月内有服用非甾体类抗炎药、皮质类固醇、四环素、双磷酸盐或者其他影响骨再生的药物者; 4.存在系统或局部的骨性疾病,如骨结核、骨炎、骨肿瘤、骨硬化症、骨软化症、严重骨质疏松等

Exclusion criteria:

1. incomplete clinical and imaging data; 2. Patients with lost visits after surgery; 3. Those who have taken non-steroidal anti-inflammatory drugs, corticosteroids, tetracycline, bisphosphonates or other drugs that affect bone regeneration within 6 months before and after surgery; 4. the existence of systemic or local bone diseases, such as bone tuberculosis, osteitis, bone tumour, osteosclerosis, osteochondrosis, severe osteoporosis, etc.

研究实施时间:

Study execute time:

From 2024-11-01 00:00:00 To 2025-06-14 00:00:00  

征募观察对象时间:

Recruiting time:

From 2024-11-01 00:00:00 To 2024-12-31 00:00:00  

干预措施:

Interventions:

组别:

行自体牙骨粉跳跃间隙植骨患者

样本量:

5

Group:

Patients with autogenous bone powder jump gap implants

Sample size:

干预措施:

干预措施代码:

Intervention:

NA

Intervention code:

组别:

行异种骨跳跃间隙植骨患者

样本量:

5

Group:

Patients undergoing allograft bone grafting of the jump gap

Sample size:

干预措施:

干预措施代码:

Intervention:

NA

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

浙江省 

市(区县):

杭州 

Country:

China 

Province:

Zhejiang 

City:

Hangzhou 

单位(医院):

浙江省人民医院 

单位级别:

三级甲等 

Institution
hospital:

Zhejiang Provincial People's Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

种植体边缘骨壁厚度

指标类型:

主要指标

Outcome:

Bone wall thickness at implant margin

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

种植体边缘骨吸收水平

指标类型:

次要指标

Outcome:

Level of bone resorption at the implant margin

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

NA

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 70 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

None

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

临床试验公共管理平台 IPD(http://www.medresman.org.cn)。

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

ResMan IPD (http://www.medresman.org.cn)

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例报告表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2024-10-14 09:51:14